Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Find out which dividend ETFs have the best expense ratios. Compare funds and learn how to select low-cost options for long-term gains.
27,005 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Bitcoin holds near $71,000 as geopolitical risk cools, yet a raft of macro factors and an ETF decision window keep th...
Lucid stock sits near $7, tempting bargain hunters. This article breaks down the real risks, the potential catalysts,...
The AI boom isn’t over. If you felt you missed the first wave, these three resilient stocks deliver real AI leverage,...
XRP rose about 2% as ETF inflows persisted, signaling continued institutional demand even as broader markets stay vol...
A speculative AI forecast, branded as Altman ChatGPT, points to a sharp XRP rally by the end of June 2026 as institut...
LNG players like Cheniere Energy have big moves ahead as expansion trains boost export capacity. This article breaks ...
A prominent analyst argues SpaceX could surge, but practical hurdles and private-market realities temper the enthusia...
A major stake sale in Albertsons by a large hedge fund sparks questions about what insiders know and how it affects t...
A Live Oak Bancshares CEO sold 20,000 shares for roughly $769,000 in mid-June. Is this a warning sign or routine dive...
Strong U.S. jobs data rekindled concerns about liquidity in crypto markets. The resilient jobs market keeps policy in...
A notable bounce in advanced micro devices stock drew attention from traders and long-term investors alike. This guid...